[76] Trevaskis, J.L., Mack, C.M., Sun, C., Soares, C.J., D'Souza, L.J., Levy, O.E., et al. 2013. Improved glucose control and reduced body weight in rodents with dual mechanism of action peptide hybrids. PLoS One 8:e7...
在5μm剂量下,GLP-1(1-37)和GLP-1(7-37)均可使大鼠胰岛素瘤RIN1046-38细胞内cAMP水平升高,但在5nM剂量下,只有GLP-1(7-37)可使cAMP水平升高 [24] 。与cAMP的增加一样,GLP-1(7-37)对RIN1046-38细胞胰岛素mRNA的刺激也比GLP-1(1-37)更大 [24] ,进一步支持GLP-1(7-37)比GLP-1(1-37)具有更...
自胰高糖素样肽-1(GLP-1)被发现以来,它已然成为一种“多面手”激素——其多种代谢调节功能被人们发现,远远超出了作为肠促胰素的经典定义。GLP-1的众多有益的靶点作用使其受体激动剂逐渐成为更多新兴的治疗领域如脂肪肝、肥胖和神经退行性疾病等的冉冉之“星”药物。时值利拉鲁肽在我国上市10周年,司美格鲁肽新上...
临床前数据表明,相较于单独GLP-1类似物或单独雌激素,GLP-1/雌激素结合产物可增强小鼠厌食、减重、促胰岛素和胰岛保存作用[83-85]。而这种GLP-1/雌激素结合物并没有雌激素独有的促子宫内膜增生的效应,仅体现GLP-1成分介导的治疗指标改善。GLP-1R靶向作用也被用来将地塞米松的抗炎特性传递到代谢相关组织。尽管糖皮...
[2] Fujita, Hiroki, et al. "The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential." Kidney international 85.3 (2014): 579-589.[3] Pabreja, Kavita, et al. "Molecular mechanisms underlying physiological and receptor pleiotropic effects ...
Glucagon-like peptide-1 causes pancreatic duodenal homeobox-1 protein translocation from the cytoplasm to the nucleus of pancreatic beta-cells by a cyclic adenosine monophosphate/protein kinase A-dependent mechanism. Endocrinology 142:1820-1827.[29] Kashima Y, Miki T, Shibasaki T, Ozaki N, Miyazaki...
[28] Wang X, Zhou J, Doyle ME, Egan JM,2001. Glucagon-like peptide-1 causes pancreatic duodenal homeobox-1 protein translocation from the cytoplasm to the nucleus of pancreatic beta-cells by a cyclic adenosine monophosphate/protein kina...
自胰高糖素样肽-1(GLP-1)被发现以来,它已然成为一种“多面手”激素——其多种代谢功能被人们发现,远远超出了作为肠促胰素的经典定义。GLP-1的众多有益的靶点作用使其受体激动剂逐渐成为更多新兴的治疗领域如脂肪肝、肥胖和神经退行性疾病等的冉冉之“星”药物。时值利拉鲁肽在我国上市10周年,司美格鲁肽新上市之...
[28] Wang, X., Zhou, J., Doyle, M.E., Egan, J.M. 2001. Glucagon-like peptide-1 causes pancreatic duodenal homeobox-1 protein translocation from the cytoplasm to the nucleus of pancreatic beta-cells by a cyclic adenosine monophosphate/protein kinase A-dependent mechanism. Endocrinology 142:...
药物靶点作用机制在研适应症药物最高研发状态(全球)药物类型在研机构GMA102/105(重组抗人GLP-1受体人源化单克隆抗体)GIP-1RGIP-1R激动剂2型糖尿病;肥胖;超重临床3期单克隆抗体鸿运华宁(杭州)生物医药有限公司(Gmax Biopharm LLC)Recombinant GLP-1 receptor agonists (Beijing Lepu)(重组GLP-1受体激动剂GIP-1RG...